

Highlights

- Online self-monitoring of mood can be used to investigate mood patterns in a cohort.
- Bipolar patients experience subsyndromal mood symptoms the majority of the time.
- No significant differences in mood variables were observed between bipolar I and II patients.
- Younger patients experience more variability in mood than older patients.
- Long-term outcomes may be improved by interventions to reduce mood variability.

Longitudinal Mood Monitoring in Bipolar Disorder: Course of Illness as Revealed Through a Short Messaging Service

Abstract

Background:

Online self-monitoring of mood can be used to investigate differences in course patterns across patient groups. This study explored the feasibility of remote symptom capture with True Colours, a self-rated online mood monitoring tool completed on a weekly basis.

Methods:

Participants with bipolar disorder (N = 297) completed weekly depression and mania questionnaires over an average of 27.5 months (range 1 –81 months). Subgroups defined by sex, age, and bipolar I vs. II status were compared on time in various mood states, number of episodes, and week-to-week mood variability.

Results:

Compliance with weekly questionnaires was generally high (median, 92% of weeks). Mood symptoms occurred for an average of 55.4% of weeks across the follow-up period. Females spent more time with hypomanic/manic and depressive symptoms and had more depressive episodes compared to males. Younger participants were found to experience more hypomanic/manic episodes and showed greater variability in mood symptoms than older participants. No significant differences in mood symptoms or variability were observed between bipolar I and II patients.

Limitations:

This was a naturalistic study with a heterogeneous cohort, and did not include a control group. True Colours does not identify mood fluctuations that may occur in the days between weekly assessments.

Conclusions:

Monitoring moods through an online tool is both feasible and informative regarding course of illness in patients with bipolar disorder. Interventions aiming to reduce mood variability and manic/hypomanic episodes in the early phases of bipolar disorder may enhance the long-term symptomatic course of the illness.

1
2
3 **Longitudinal Mood Monitoring in Bipolar Disorder:**
4 **Course of Illness as Revealed Through a Short Messaging Service**
5

6
7 Rebecca F McKnight¹ BMBCh, MRCPsych, Amy C Bilderbeck PhD¹, David J Miklowitz PhD^{1,2},
8 Christopher Hinds¹, Guy M Goodwin PhD, FMedSci¹, John R Geddes MD FRCPsych¹.
9

10 1 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, OX3 7JX, UK.

11 Correspondence: rebecca.mcknight@psych.ox.ac.uk

12 2 UCLA Semel Institute for Neuroscience and Human Behavior, Division of Child and Adolescent
13 Psychiatry & David Geffen School of Medicine at UCLA, Los Angeles, USA.
14

15
16 **Running title (max 40 characters):** Longitudinal mood and bipolar disorder
17
18
19
20
21

1 **Abstract**

2 **Background:**

3 Online self-monitoring of mood can be used to investigate differences in course patterns across
4 patient groups. This study explored the feasibility of remote symptom capture with True Colours, a
5 self-rated online mood monitoring tool completed on a weekly basis.

6 **Methods:**

7 Participants with bipolar disorder (N = 297) completed weekly depression and mania questionnaires
8 over an average of 27.5 months (range 1 –81 months). Subgroups defined by sex, age, and bipolar I
9 vs. II status were compared on time in various mood states, number of episodes, and week-to-week
10 mood variability.

11 **Results:**

12 Compliance with weekly questionnaires was generally high (median, 92% of weeks). Mood
13 symptoms occurred for an average of 55.4% of weeks across the follow-up period. Females spent
14 more time with hypomanic/manic and depressive symptoms and had more depressive episodes
15 compared to males. Younger participants were found to experience more hypomanic/manic
16 episodes and showed greater variability in mood symptoms than older participants. No significant
17 differences in mood symptoms or variability were observed between bipolar I and II patients.

18 **Limitations:**

19 This was a naturalistic study with a heterogeneous cohort, and did not include a control group. True
20 Colours does not identify mood fluctuations that may occur in the days between weekly
21 assessments.

22 **Conclusions:**

23 Monitoring moods through an online tool is both feasible and informative regarding course of illness
24 in patients with bipolar disorder. Interventions aiming to reduce mood variability and
25 manic/hypomanic episodes in the early phases of bipolar disorder may enhance the long-term
26 symptomatic course of the illness.

1

2

3 **Keywords:** Remote monitoring, patient reported outcomes, digital health technologies, mood

4 instability, mania, depression

5

6

7 **List of Abbreviations**

8 BD = Bipolar Disorder

9 IQR = Interquartile Range

10 QIDS = Quick Inventory of Depression Symptomatology

11 ASRM = Altman Self-Rating Mania Scale

12

BACKGROUND

Most modern treatment guidelines are oriented toward an episodic model of bipolar disorder (BD) in which the focus is on the treatment and prevention of acute episodes. The course of bipolar disorder, however, is highly heterogeneous. Although distinct episodes are clearly present in the majority of patients, many have significant inter-episode mood instability rather than euthymia (Henry et al., 2008; MacQueen et al., 2003). Mood instability – usually described as rapid and frequent movement away from the euthymic state – appears to lower the threshold for relapse into more severe mood episodes and has a chronic negative impact upon quality of life and functional ability (Bauer et al., 2009; Judd et al., 2000; Perlis et al., 2006). Mood instability is both a key feature of both bipolar 1 and bipolar 2 disorder (Judd and Akiskal, 2003; Judd et al., 2003; Judd et al., 2002) and a risk factor for developing BD (Howes et al., 2011).

Standard clinical assessments – such as the Life Chart methodology – are retrospective, with the inherent problem of recall bias (Denicoff et al., 1997). Further, course of illness data have usually been measured in small samples followed over short time periods (Denicoff et al., 2000). There is some evidence that paper-based daily mood monitoring can provide detailed mood variability data, but is practical only over short periods (Proudfoot et al., 2014). A reliable method of daily or weekly mood recording using remote monitoring may facilitate recognition of prodromal symptoms of new episodes. The increasing accessibility of portable and wearable technologies enables the tracking of both subjective and objective data related to mood and functioning (Faurholt-Jepsen et al., 2015a; Faurholt-Jepsen et al., 2015b). Such approaches have been found to be both acceptable and feasible in patients with serious mental illness (Naslund et al., 2015).

To date, only a few studies have described the use of such technology in BD, or reported mood data gathered by this method. Scharer et al (2002) reported a feasibility study in which they adapted the National Institute of Mental Health Prospective Life-Chart Form for use on a handheld computer (Scharer et al., 2002). Patients found this a preferable method to written forms and found it beneficial to be playing an active role in their treatment. Similarly, Bauer et al used a home

1 computer based mood monitoring system in BD and reported a very low rate of missing data (Bauer
2 et al., 2004). The only study to date to compare a clinician-rated mood scale to a self-reported
3 computer scale in BD found high correlations between the two methods (Chinman et al., 2004).
4 There are also numerous publically available smartphone/tablet applications for personal mood
5 monitoring available. A systematic review of in 2015 suggested that whilst these are a potentially
6 therapeutic tool, those available at present are not written along evidence-based lines and primarily
7 do not use validated mood rating approaches (Nicholas et al., 2015).

8 Our group has demonstrated the feasibility of using a remote monitoring system ("True
9 Colours") for the prospective collection of self-reported symptom ratings in bipolar disorder using
10 text messaging, email, and internet-based technologies (Bopp et al., 2010; Miklowitz et al., 2012).
11 Supporting the validity of this form of data collection, patient reported outcomes collected via True
12 Colours have provided the basis for linking mood instability to biases in cognition in bipolar disorder.
13 Longitudinal collection of self-report data via True Colours also formed the basis of evaluating a
14 psychoeducational intervention for bipolar disorder (Bilderbeck et al., 2016). Thus, our motivation
15 for developing this system has been manifold, including the potential for large volumes of curated
16 data to provide insights into patterns of illness. In addition, access to one's own mood reports can
17 help patients to understand and manage their illness more effectively, potentially improving clinical
18 outcomes and reducing the need for high intensity professional input.

19 Here, we aimed to describe the range of mood phenotypes experienced by a new larger
20 cohort of bipolar patients. More specifically, we aimed to examine the acceptability of the True
21 Colours system, understand and quantify the course of mood symptoms experienced in BD, and
22 examine course patterns using a mood variability score.

25 **METHODS**

26 **The OXTEXT-1 Cohort**

OXTEXT-1 is a cohort study of participants (≥ 16 years of age) with a DSM-IV diagnosis of bipolar disorder type I, 2 or not-otherwise-specified (NOS) (APA, 2000). The diagnosis of cyclothymia was excluded. To qualify for inclusion, patients must also be in treatment with a psychiatrist and be willing to use SMS/internet to monitor their mood. Patients are recruited from Oxfordshire and surrounding counties through outpatient psychiatric clinics, inpatient wards, advertising in other local health services and general practitioners. All participants attend a 3hr screening and assessment session, during which they complete a clinical interview which is conducted by a member of the research team and audio-recorded for later confirmation of diagnosis by a research psychiatrist. All patients are provided with training for and are registered to use the True Colours remote monitoring system (see below). Whilst enrolled in the cohort individuals continue treatment as usual, consisting of contact with an outpatient psychiatrist, medications, psychological treatments and admission to hospital if necessary. OXTEXT-1 is not a treatment intervention: for information and risk monitoring purposes, treating psychiatrists receive the weekly data submitted by their patients and it is available to patients online.

Patients can be in any mood state at enrolment but must have capacity to give consent: those who are too unwell initially are contacted again once their mood stabilises. Written informed consent is obtained from all patients before registration in the cohort; ethical approval was granted by Oxfordshire REC 'A' (REC reference number 10/H0604/13). Recruitment into the cohort began in 2010 and is ongoing. Here, data were extracted and analysed from all participants (N=367) recruited between 8th July 2010 and 7th August 2013.

True Colours Prospective Mood Monitoring

The True Colours symptom monitoring system uses SMS texting and email to provide an inexpensive and practical means of submitting and reviewing self-reported symptom data for patients and clinicians. Participants are requested by a weekly SMS/email (at a time and day specified by the patient) to reply with responses to a depression scale (Quick Inventory of Depressive

Symptomatology, a 16-item self-report version [QIDS-SR]) (Rush et al., 2003) and a mania scale (Altman Self-Rating Mania Scale [ASRM]) (Altman et al., 1997). Patients are given convenient mini versions of the scales and merely need to respond with a series of digits representing their question answers. One prompt is sent if a response is not received within 24 hours. True colours is an ongoing system with no set participation time. The True Colours system has been described in more detail elsewhere (Bopp et al., 2010).

Statistical Analysis

A macro within Microsoft Excel (Microsoft, 2010) was used to estimate the proportion of missing data and proportion of full days a patient had spent in each mood state. Missing data were defined as any 7-day period during which no data were received. Mood states were defined as per the validated questionnaire cut-offs: a mood episode was defined as being ASRM >5 for >1 consecutive week (Altman et al., 1997) (mania) and/or QIDS>10 (Rush et al., 2003) for >2 consecutive weeks (depression). Concurrent scores of ASRM >5 and QIDS >10 were seen as indicative of a mixed state.

Mood instability was calculated as a root mean square successive difference score (rmssd): the square-root of the number of mood changes per week, where one change is a one integer change in QIDS/ASRM score (Gershon, 2015; Jahng S, 2008). The square root function was used to allow a wide spread of variation values to be easily compared. For example, if the QIDS score was 4,5,7 on weeks 1,2,3, there would be 1 change between weeks 1 and 2, and 2 changes between weeks 2 and 3. Squaring and summing these change gives a total of 5 over 3 weeks or 2.5 changes per transition-point. Variability would thus be calculated as $\sqrt{2.5} = 1.58$ (Jahng et al., 2008). Evidence is starting to emerge of the relevance of rmssd scores to the treating clinician (Stange et al., 2016).

Most of the variables were positively skewed (i.e., more patients reported lower scores on the QIDS and ASRM than higher scores). Non-parametric analyses (i.e., Kruskal-Wallis one-way analysis of variance for age and diagnosis, and the Wilcoxon Rank Sum test for gender) were used to

compare between groups (gender, age, diagnosis) using a significant alpha <0.05. Independent variables included age (<20 years, 21-40, 41-60, >60 years), gender and diagnosis (bipolar 1,2,NOS); dependent variables were time spent in mood state, mood episodes per year and mood variability score. Cohen's D was used to calculate effect sizes. SPSS.v.20 was used for all calculations (2011).

RESULTS

Characteristics of the OXTEXT-1 cohort

Thirty-nine participants had withdrawn from OXTEXT-1 since enrolment, and six were lost to follow-up, leaving 297 active participants (91.7%). 66.9% of the cohort were female with a mean age of 41 years [SD \pm 13, range 16-76]. The baseline characteristics of the participants are shown in Table 1. Of these 297 participants, current medication data was only available for 265 (89%) due to procedural changes during the course of the trial.

1

[Table 1 about here]**2 Table 1. Baseline Characteristics of OXTEXT-1 Cohort (N=297)**

Characteristic	Percentage	Mean	SD	Range
Age, years		41	13.7	16-76
Female	66.7%			
Ethnicity				
White European	93.5%			
Mixed Black	1.55%			
Mixed Asian	0.31%			
Other	5.64%			
Educational Level				
Undergraduate degree or above	55.2%			
A-levels or equivalent (age 18)	23.6%			
GCSEs or equivalent (age 16)	16.1%			
DSM-IV Diagnosis				
Bipolar 1	62.6%			
Bipolar 2	33.3%			
Bipolar NOS	4.0%			
Age of onset of first depressive episode, years		21.3	9.7	4-57
Mean number of (self-reported) lifetime episodes of depression		22.8	27.5	1-100
Age of onset of first hypomanic/manic symptoms		26.0	11.5	3-72
Number of (self-reported) lifetime episodes of hypomania/mania		Mean: 17.2 Median: 6	22.8 4.4	1-100
Has ever had ≥4 mood episodes in one year	64.7%			
Has ever experienced psychotic symptoms	48.5%			
Patient has ever attempted to take their own life	38.9%			
Proportion of lifetime patient reports having spent unwell since onset of mood disorder				
0-49%	36.5%			
50-100%	28%			
Unknown	35.5%			
Length of time using True Colours System (months)		27.6	22.5	1-81 [Median: 21 months]
Medication at entry into study*				
Lithium	32.8%			
Anticonvulsant	42.2%			
Antipsychotic	44.1%			
Antidepressant	37.0%			
Drug free	9.1%			

3 *Medication data shown as percentages of the 265 (89%) of study participants for whom this data
4 was available.

Compliance and acceptability of the True Colours System

Patients in the cohort used the system for an average of 27.5 ± 22.5 months (range 1-81). The mean time between text messages and emails being received by the research team was 8.2 days; this approximates to one response to the text message or email prompt per week. 74% of responses were received by SMS. For the ASRM and QIDS, there was a median of 7.9% (interquartile range [IQR] 0-4.1) and 7.8% (IQR 0-2.7) of weeks with missing data. There was no significant difference in the amount of missing data between genders, diagnostic subtypes or when patients had submitted scores above validated cut-offs (compared to below) the previous week. Participants were equally likely to complete the ASRM and QIDS scales throughout the follow-up period.

Symptomatic experience of the OXTEXT-1 cohort

The OXTEXT-1 cohort reported some level of mood symptoms for 55.4% of the period of follow up. Mild depression accounted for one-quarter of the time [QIDS 5-10: median 23.1% (IQR 10.5-38.9)], moderate depression for one-sixth [QIDS 11-15: 10.4% (2.8-21.9)] and severe depression and very severe depression for approximately 10% and 4%, respectively [QIDS 16-20: 2.6% (0-12.6), QIDS>20: 0.00% (0.0-0.34)]. The participants reported hypomanic/manic symptoms on an average of 7.5% weeks [ASRM>5, median 7.5% (IQR 0.89-24.0)]. Symptoms consistent with the diagnosis of a mixed state (ASRM>5 & QIDS>10) were infrequent (median % of spent in a mixed state 0.00% (0.00-3.46)). Overall, 52.5% of the cohort reported at least one week at an ASRM score> 10 and 87.5% at least one week at QIDS>10. The overall percentage of time spent with an ASRM>10 was 6.4%. The median number of hypomanic/manic episodes per year (i.e. at ASRM>5) was 1.78 [IQR 0.41-3.3] and depressive episodes 2.09 [0.41-4.89].

Effects of Gender and Age on Percentage of Time with Mood Symptoms

Females spent significantly more time with hypomanic or manic symptoms than men [ASRM>5: females median 8.23% (IQR 1.3-24.2) vs. males, 5.62% (IQR 0.63-22.6), Cohen's d effect size 0.32

(95% CI 0.07-0.56), $p=0.009$] but there was no difference in the number of hypomanic/manic episodes between genders (Figure 2). Females experienced significantly more depressive episodes per year than males [2.16 (IQR 0.76-3.62) vs. 0.86 (IQR 0-2.53), ES 0.46 (0.24-0.70), $p<0.001$] and spent more days moderately depressed [females median 11.8% (IQR 4.1-23.8) v. males 7.10% (IQR 0.8-17.9), ES 0.14 (0.38-1.0), $p<0.01$]. Overall females spent more time depressed than men (Figure 2).

No significant difference in the amount of time spent manic, hypomanic or depressed was found between any age group. There was no significant difference in the severity of depression reported by different age groups. However, younger participants had significantly more manic/hypomanic episodes per year than older participants [age <20, mean = 6.47 (2.8-8.8) vs. ages 21-40 yrs, mean= 1.64 [0.55-3.8]; ES = 0.79 (0.2-1.38), $p=0.001$].

Comparison of Course Patterns in Patients with Bipolar I, Bipolar II, or Bipolar NOS Disorder

There was no difference in the amount of time spent depressed (QIDS>10) between those diagnosed with bipolar 1, 2 or NOS. There was no difference in the time spent with differing severity of depressive symptoms between the three diagnoses, or with hypomanic/manic symptoms. There was no significant difference in the number of mood episodes per year – at either pole – between diagnostic subgroups.

Mood Variability as Reflected by Root mean squared Successive Difference Scores

Overall the cohort experienced an average QIDS variability score of 1.55 [SD 0.54] and ASRM variability score of 1.21 [SD 0.7] (Table 2). The mean weekly score change for QIDS was 2.4 and 1.44 for ASRM, indicating an average 1-2 point scale change per week. Females reported a significantly greater change in weekly QIDS scores than males, but this was not the case for the ASRM [QIDS: mean 1.61 [SD 0.56] vs. 1.42 [0.51], ES 0.35 (0.1-0.55) $p=0.001$; ASRM: 1.24 [0.58] vs. 1.16 [0.59], ES 0.14 (-0.1- 0.38), $p=0.323$]. There was no difference in variability between diagnostic subgroups on

1 either the QIDS or ASRM. Younger participants reported significantly more variability on both the
2 QIDS and ASRM than older participants [QIDS: <20yrs 1.88 [SD 0.71] vs. >60yrs 1.31 [0.40], ES 1.12
3 (0.38-1.81), $p < 0.0001$, ASRM: 1.67 [0.7] vs. 0.94 [0.46], ES 1.35 (0.59-2.06) $p = 0.001$].

4 5 **DISCUSSION**

6 Systems such as True Colours may be of considerable clinical value, as doctors and patients
7 may be able to collaborate in identifying episodes at their earliest, and intervene to prevent
8 escalation. Mood monitoring is also fundamental to self-management approaches, enabling patients
9 to gain insights into the ongoing relationship between behaviour (e.g. sleep patterns) and mood
10 states. We aimed to describe the range of mood phenotypes reported by a cohort of bipolar patients
11 using True Colours mood monitoring over a period of up to 81 months. Our findings are based on
12 data drawn from a large, naturalistically recruited cohort with relatively little missing data, and
13 which is comparable with others in terms of mean age, age of illness onset, proportions by gender
14 and ethnicity (Joffe et al., 2004; Judd et al., 2002; Kupfer et al., 2002; Suppes et al., 2001), and level
15 of education (Suppes et al., 2001). Our results suggest that mood symptoms are experienced by
16 patients the majority of the time, and that age and gender, but not diagnostic subgroup, influence
17 symptoms collected over an average period of 27.5 months.

18 This was a study of predictors of mood cycling within patients with bipolar disorder.
19 Therefore, we did not include a comparison group of healthy individuals to evaluate how frequently
20 mood episodes or changes occur in the general population. However, a new study has been
21 published that followed bipolar and healthy control individuals using the True Colours system for up
22 to 52 weeks (Tsanas et al., 2016). The study reported that patients with BD and patients with
23 borderline personality disorder both consistently reported higher levels of mania, depression, and
24 anxiety than healthy controls. Thus, True Colours ratings of moods are unlikely to reflect the day-to-
25 day variability in mood states that is common in the general population.

1 We found very high rate of compliance (92%) with the True Colours system; comparable to
2 those reported by similar technologies (Bauer et al., 2004). True Colours was designed to be flexible,
3 convenient & personalised: patients can choose the frequency and timing of prompts, send in extra
4 information and access their graphs on any internet-enabled device. The high rate of compliance
5 suggests these qualities are attractive to patients, perhaps more so than a system requiring access to
6 a conventional computer or that must be completed at a set time each week. 74% of participants
7 returned responses by SMS, with the remainder by e-mail (10%) or a mixture of the two methods,
8 suggesting that having a choice of communication methods is likely to enhance patient experience
9 and compliance.

10 Whereas patients reported mood symptoms between 50-60% of the time, symptoms
11 meeting diagnostic criteria for an episode only occurred about twice per year for each illness pole
12 (an average of 4 recurrences per patient). This pattern suggests that patients experience ongoing
13 subsyndromal symptoms a large proportion of the time. These findings are consistent with the view
14 of BD as a condition of chronic mood instability with episodic exacerbations rather than an episodic
15 disorder with return to baseline in between episodes. This study also confirms previous findings that
16 depressive symptoms occur for longer intervals than hypomanic or manic symptoms; here we found
17 a ratio of 9 weeks:1 week (Bopp et al., 2010; Joffe et al., 2004; Judd et al., 2002; Kupka et al., 2007;
18 Post et al., 2003). This ratio is much higher than that found by life-chart methodology publications,
19 possibly due to our use of a more sensitive measure of depression, our use of self-report rather than
20 clinician-reported symptoms, and/or the use of prospective monitoring rather than techniques
21 dependent on retrospective recall (Judd and Akiskal, 2003). As discussed further below, the Altman
22 self-rating scale may not capture subthreshold variations in hypomania to the degree observed with
23 Life Chart methodology. It is unclear whether depression is inherently more prominent in BD than
24 mania, given that patients have a tendency to under-report mania (Youngstrom, 2015) and that
25 mood stabilizing medications and second generation antipsychotics are more effective for
26 controlling manic than depressive symptoms.

Several other publications using life chart or computer-based mood monitoring systems have collected data similar to ours; these are summarised in Table 3. Most studies find no significant difference in the mood states over time of patients with bipolar I or 2 disorders. We also observed no difference in variability of depressive or manic mood symptoms between the diagnostic subgroups. Together, these data suggest that the long-term course of bipolar I and II disorder are more similar than different, although effective treatments for the two subtypes may differ.

We observed that females reported more weeks with depression and hypomanic/manic symptoms than males. In some previous reports females with BD were observed to spend more time with depressive symptoms compared to male patients (Kupfer et al., 2002; Nivoli et al., 2011; Taylor and Abrams, 1981) although this pattern has not been consistent (Diflorio and Jones, 2010). Female participants also reported a significantly higher variability in depressive scores. As discussed by other investigators, differences between females and males in mood symptoms may have a variety of causes, including differences in reporting thresholds, the tendency to ruminate when depressed, hormonal changes that vary with age, and patterns of alcohol abuse (Frye et al., 2003; Picinelli and Wilkinson, 2000)

To the best of our knowledge, ours is the first report linking age with self-reported mood stability. We observed that younger patients experienced more episodes of mania or hypomania and more mood variability compared to their older counterparts, in concordance with previous reports suggesting that younger patients experience more severe manic episodes than older patients and show greater illness severity (Broadhead and Jacoby, 1990; Depp and Jeste, 2004). Frequent mood variability in the early phases of BD, even if the variability is subsyndromal, may signal the need for more aggressive pharmacological or psychosocial interventions to prevent a more recurrent course of illness.

Study Limitations

The cohort, recruited primarily from Oxfordshire and the surrounding counties, is almost entirely British and Caucasian, and has a higher than average level of education. Within the

1 inclusions criteria, it is a clinically heterogeneous sample. The True Colours system excludes patients
2 who do not feel able to use email/SMS as a method of communication or do not have access to the
3 internet. However, only one patient referred to the OXTEXT study did not consent due to
4 communication difficulties. One patient used an adapted system where they telephoned in the
5 mood scores weekly.

6 Instruments that measure subthreshold levels of hypomanic or manic symptomatology, for
7 example, the Internal State Scale (Bauer et al., 2000), may prove more sensitive in assaying manic
8 symptoms than the ASRM. Additionally, collecting data from family members may increase the
9 sensitivity of all self-report instruments, especially among patients with significantly elevated mood.
10 Whilst the QIDS is anchored to the DSM-IV, neither it nor the ASRM are validated as diagnostic tools,
11 so they should be used as indices of the severity of current symptoms rather than syndromal onset
12 or offset.

13 One limitation of the True Colours system is that the individual's mood states are treated as
14 static between weekly measurements. Indeed, some participants may have had exacerbations of
15 manic or hypomanic symptoms in the days between weekly ratings. More frequent monitoring could
16 provide important clinical information on daily or intra-daily mood fluctuations that might be used to
17 distinguish patients who, for example, would meet the course specifier criteria for rapid cycling or
18 who might be diagnosed with a comorbid borderline personality disorder (Tsanas et al., 2016).
19 However, there is no evidence that daily rather than weekly monitoring improves validity, and it is
20 possible that daily monitoring would result in poorer compliance. In future research, we intend to
21 investigate variations in latency between a patient receiving a prompt and returning mood data.

22 This study was also limited by the lack of measures of stressful life events, which may have
23 predated or occurred in tandem with changes in mood. The study was not designed to answer
24 questions about the relationship between stress and mood cycling in bipolar disorder. We see this as
25 a fruitful area for exploration, with the proviso that life events reported by patients on a mood

tracking device may not accurately reflect the specifics of these events or how they were affected by his/her behaviour.

This study did not include a comparison sample of healthy volunteers who made weekly mood ratings. Thus, we are unable to conclude that the observed mood fluctuations reflect the diagnosis of bipolar disorder or normal variations in mood that can be detected when individuals provide self-ratings over a 2-year interval. Additionally, future studies with psychiatric comparison groups (e.g., patients with personality disorders) may help clarify whether there are patterns of mood fluctuation that are truly “signatures” of bipolar disorder.

Finally, concurrent psychopharmacological information for our cohort was only available for 89% of participants and at the point of enrolment. An analysis of the time-lagged relationships between changes in specific medications or dosing plans and mood variations was not possible at this stage.

Conclusions

Our results suggest that mood symptoms are experienced by patients the majority of the time, and that classically defined episodes of depression and mania are superimposed upon subsyndromal mood symptoms, including pervasive mood instability. Age and gender, but not diagnostic subgroup, influenced our longitudinal symptom data, with females reporting more depressive episodes and more time hypomanic/manic than males, and younger patients experiencing greater mood variability than older patients. Longitudinal mood monitoring using electronic data collection methods are increasingly likely to contribute to our understanding of the course of bipolar disorder and its response to various treatments or self-management strategies.

Consent for Publication

Not applicable

Acknowledgements & Role of the Funding Source

We thank the OXTEXT team for their hard work in recruiting to the cohort; Angus McKnight for writing a macro; Merryn Voysey for statistical advice; and Zoe Reed for assistance in editing the manuscript. JG had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Reference Number RP-PG-0108-10087). JG is a NIHR Senior Investigator. We also acknowledge the provision of facilities for conducting the study by the Oxford cognitive health Clinical Research Facility (NIHR funded), Warneford Hospital, Oxford. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. ACB and LA are supported by a Wellcome Trust Strategic Award (CONBRIO: Collaborative Oxford Network for Bipolar Research to Improve Outcomes, Reference number 102616/Z). The design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript was entirely independent of the funding sources.

Competing Interests

GMG reports grants and personal fees from Servier, personal fees from Teva, personal fees from Otsuka, personal fees from Takeda, grants and personal fees from Lundbeck, personal fees from Eisai, personal fees from Lilly, personal fees from Merck, personal fees from GlaxoSmithKline, personal fees from AstraZeneca, and grants from P1vital during the conduct of the study. DJM reports grants from American Foundation for Suicide Prevention and National Institute of Mental Health; and book royalties from Guilford Press and John Wiley and Sons, outside the submitted work. ACB has received salaries from P1vital. All other authors declare no conflicts of interest.

Author's Contributions

RM downloaded data, designed and performed analyses and results interpretation and drafted the manuscript. ACB assisted with reference research and helped to draft the manuscript. DJM, GMG, JFG initiated the OXTEXT project, helped design the methodology, helped to interpret findings and provided guidance with the manuscript. CH performed the variability design and analysis. JFG is guarantor.

Reference List

2011. SPSS Statistics for Windows V.20. SPSS Ltd., Chicago, USA.
- Altman, E.G., Hedeker, D., Peterson, J.L., Davis, J.M., 1997. The Altman Self-Rating Mania Scale. *Biological Psychiatry* 42, 948-955.
- APA, 2000. Diagnostic and statistical manual of mental disorders 4th edition, text revision ed. American Psychiatric Association, Washington DS.
- Bauer, M., Glenn, T., Grof, P., Rasgon, N.L., Marsh, W., Sagduyu, K., Alda, M., Lewitzka, U., Sasse, J., Kozuch-Krolik, E., Whybrow, P.C., 2009. Frequency of subsyndromal symptoms and employment status in patients with bipolar disorder. *Social Psychiatry and Psychiatric Epidemiology* 44, 515-522.
- Bauer, M., Grof, P., Gyulai, L., Rasgon, N., Glenn, T., Whybrow, P.C., 2004. Using technology to improve longitudinal studies: self-reporting with ChronoRecord in bipolar disorder. *Bipolar Disorders* 6, 67-74.
- Bauer, M.S., Vojsa, C., Kinosian, B., Altshuler, L., Glick, H., 2000. The Internal State Scale: replication of its discriminating abilities in a multisite, public sector sample. *Bipolar Disorders* 2, 340-346.
- Bilderbeck, A.C., Atkinson, L.Z., McMahon, H.C., Voysey, M., Simon, J., Price, J., Rendell, J., Hinds, C., Geddes, J.R., Holmes, E., Miklowitz, D.J., Goodwin, G.M., 2016. Psychoeducation and online mood tracking for patients with bipolar disorder: A randomised controlled trial. *Journal of Affective Disorders* 205, 245-251.
- Bopp, J.M., Miklowitz, D.J., Goodwin, G.M., Stevens, W., Rendell, J.M., Geddes, J.R., 2010. The longitudinal course of bipolar disorder as revealed through weekly text messaging: a feasibility study. *Bipolar Disorders* 12, 327-334.
- Broadhead, J., Jacoby, R., 1990. Mania in Old-Age - a 1st Prospective-Study. *Int J Geriatr Psych* 5, 215-222.
- Chinman, M., Young, A.S., Schell, T., Hassell, J., Mintz, J., 2004. Computer-assisted self-assessment in persons with severe mental illness. *Journal of Clinical Psychiatry* 65, 1343-1351.
- Denicoff, K.D., Leverich, G.S., Nolen, W.A., Rush, A.J., McElroy, S.L., Keck, P.E., Suppes, T., Altshuler, L.L., Kupka, R., Frye, M.A., Hatef, J., Brotman, M.A., Post, R.M., 2000. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM (TM)-p) for longitudinal assessment of bipolar illness. *Psychological Medicine* 30, 1391-1397.
- Denicoff, K.D., SmithJackson, E.E., Disney, E.R., Suddath, R.L., Leverich, G.S., Post, R.M., 1997. Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p). *Journal of Psychiatric Research* 31, 593-603.
- Depp, C.A., Jeste, D.V., 2004. Bipolar disorder in older adults: a critical review. *Bipolar Disord* 6, 343-367.
- Diflorio, A., Jones, I., 2010. Is sex important? Gender differences in bipolar disorder. *Int Rev Psychiatr* 22, 437-452.
- Faurholt-Jepsen, M., Brage, S., Vinberg, M., Jensen, H.M., Christensen, E.M., Knorr, U., Kessing, L.V., 2015a. Electronic monitoring of psychomotor activity as a supplementary objective measure of depression severity. *Nordic Journal of Psychiatry* 69, 118-125.
- Faurholt-Jepsen, M., Ritz, C., Frost, M., Mikkelsen, R.L., Christensen, E.M., Bardram, J., Vinberg, M., Kessing, L.V., 2015b. Mood instability in bipolar disorder type I versus type II-continuous daily electronic self-monitoring of illness activity using smartphones. *Journal of Affective Disorders* 186, 342-349.
- Frye, M.A., Altshuler, L.L., McElroy, S.L., Suppes, T., Keck, P.E., Denicoff, K., Nolen, W.A., Kupka, R., Leverich, G.S., Pollio, C., Grunze, H., Walden, J., Post, R.M., 2003. Gender Differences in Prevalence, Risk, and Clinical Correlates of Alcoholism Comorbidity in Bipolar Disorder. *Am J Psychiat* 160, 883-889.

Gershon, A.a.P.E., 2015. Inter-episode affective intensity and instability: Predictors of depression and functional impairment in bipolar disorder. *Journal of Behavior Therapy and Experimental Psychiatry*, 14-18.

Henry, C., Van den Bulke, D., Bellivier, F., Roy, I., Swendsen, J., M'Bailara, K., Siever, L.J., Leboyer, M., 2008. Affective lability and affect intensity as core dimensions of bipolar disorders during euthymic period. *Psychiatry Research* 159, 1-6.

Howes, O.D., Lim, S., Theologos, G., Yung, A.R., Goodwin, G.M., McGuire, P., 2011. A comprehensive review and model of putative prodromal features of bipolar affective disorder. *Psychol Med* 41, 1567-1577.

Jahng, S., Wood, P.K., Trull, T.J., 2008. Analysis of affective instability in ecological momentary assessment: Indices using successive difference and group comparison via multilevel modeling. *Psychological Methods* 13, 354-375.

Jahng S, W.P., Trull TJ. , 2008. Analysis of affective instability in ecological momentary assessment: Indices using successive difference and group comparison via multilevel modeling. *Psychological Methods*. 13, 354-375.

Joffe, R.T., MacQueen, G.M., Marriott, M., Young, L.T., 2004. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. *Bipolar Disorders* 6, 62-66.

Judd, L.L., Akiskal, H.S., 2003. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. *Current psychiatry reports* 5, 417-418.

Judd, L.L., Akiskal, H.S., Schettler, P.J., Coryell, W., Endicott, J., Maser, J.D., Solomon, D.A., Leon, A.C., Keller, M.B., 2003. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. *Archives of General Psychiatry* 60, 261-269.

Judd, L.L., Akiskal, H.S., Schettler, P.J., Endicott, J., Maser, J., Solomon, D.A., Leon, A.C., Rice, J.A., Keller, M.B., 2002. The long-term natural history of the weekly symptomatic status of bipolar I disorder. *Archives of General Psychiatry* 59, 530-537.

Judd, L.L., Paulus, M.J., Schettler, P.J., Akiskal, H.S., Endicott, J., Leon, A.C., Maser, J.D., Mueller, T., Solomon, D.A., Keller, M.B., 2000. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? *Am. J. Psychiat.* 157, 1501-1504.

Kupfer, D.J., Frank, E., Grochocinski, V.J., Cluss, P.A., Houck, P.R., Stapf, D.A., 2002. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. *J Clin Psychiat* 63, 120-125.

Kupka, R.W., Altshuler, L.L., Nolen, W.A., Suppes, T., Luckenbaugh, D.A., Leverich, G.S., Frye, M.A., Keck, P.E., Jr., McElroy, S.L., Grunze, H., Post, R.M., 2007. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. *Bipolar Disorders* 9, 531-535.

MacQueen, G.M., Marriott, M., Begin, H., Robb, J., Joffe, R.T., Young, L.T., 2003. Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. *Bipolar Disorders* 5, 349-355.

Microsoft, 2010. Microsoft Excel 2010. Microsoft, Washington D.C, USA.

Miklowitz, D.J., Price, J., Holmes, E.A., Rendell, J., Bell, S., Budge, K., Christensen, J., Wallace, J., Simon, J., Armstrong, N.M., McPeake, L., Goodwin, G.M., Geddes, J.R., 2012. Facilitated Integrated Mood Management for adults with bipolar disorder. *Bipolar Disord* 14, 185-197.

Naslund, J.A., Marsch, L.A., McHugo, G.J., Bartels, S.J., 2015. Emerging mHealth and eHealth interventions for serious mental illness: a review of the literature. *J Ment Health*, 1-12.

Nicholas, J., Larsen, M.E., Proudfoot, J., Christensen, H., 2015. Mobile Apps for Bipolar Disorder: A Systematic Review of Features and Content Quality. *J. Med. Internet Res.* 17, 14.

Nivoli, A.M.A., Pacchiarotti, I., Rosa, A.R., Popovic, D., Murru, A., Valenti, M., Bonnin, C.M., Grande, I., Sanchez-Moreno, J., Vieta, E., Colom, F., 2011. Gender differences in a cohort study of 604 bipolar patients: The role of predominant polarity. *J Affect Disorders* 133, 443-449.

Perlis, R.H., Brown, E., Baker, R.W., Nierenberg, A.A., 2006. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. *Am. J. Psychiat.* 163, 225-231.

Picinelli, M., Wilkinson, G., 2000. Gender differences in depression. *Critical review* 177, 486-492.

Post, R.M., Denicoff, K.D., Leverich, G.S., Altshuler, L.L., Frye, M.A., Suppes, T.M., Rush, A.J., Keck, P.E., McElroy, S.L., Luckenbaugh, D.A., Pollio, C., Kupka, R., Nolen, W.A., 2003. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH Life Chart Method. *Journal of Clinical Psychiatry* 64, 680-690.

Proudfoot, J., Whitton, A.E., Parker, G., Manicavasagar, V., Nicholas, J., Smith, M., 2014. Evidence of weekly cyclicality in mood and functional impairment in those with a bipolar disorder. *Psychiatry Research* 218, 290-294.

Rush, A.J., Trivedi, M.H., Ibrahim, H.M., Carmody, T.J., Arnow, B., Klein, D.N., Markowitz, J.C., Ninan, P.T., Kornstein, S., Manber, R., Thase, M.E., Kocsis, J.H., Keller, M.B., 2003. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. *Biological Psychiatry* 54, 573-583.

Scharer, L.O., Hartweg, V., Valerius, G., Graf, M., Hoern, M., Biedermann, C., Walser, S., Boensch, A., Dittmann, S., Forsthoef, A., Hummel, B., Grunze, H., Walden, J., 2002. Life charts on a palmtop computer: first results of a feasibility study with an electronic diary for bipolar patients. *Bipolar Disorders* 4, 107-108.

Stange, J.P., Sylvia, L.G., Magalhaes, P.V.D., Miklowitz, D.J., Otto, M.W., Frank, E., Yim, C., Berk, M., Dougherty, D.D., Nierenberg, A.A., Deckersbach, T., 2016. Affective instability and the course of bipolar depression: results from the STEP-BD randomised controlled trial of psychosocial treatment. *British Journal of Psychiatry* 208, 352-358.

Suppes, T., Leverich, G.S., Keck Jr, P.E., Nolen, W.A., Denicoff, K.D., Altshuler, L.L., McElroy, S.L., Rush, A.J., Kupka, R., Frye, M.A., Bickel, M., Post, R.M., 2001. The Stanley Foundation Bipolar Treatment Outcome Network: II. Demographics and illness characteristics of the first 261 patients. *J Affect Disorders* 67, 45-59.

Taylor, M.A., Abrams, R., 1981. Gender Differences in Bipolar Affective-Disorder. *J Affect Disorders* 3, 261-271.

Tsanas, A., Saunders, K.E.A., Bilderbeck, A.C., Palmius, N., Osipov, M., Clifford, G.D., Goodwin, G.M., De Vos, M., 2016. Daily longitudinal self-monitoring of mood variability in bipolar disorder and borderline personality disorder. *Journal of Affective Disorders* 205, 225-233.

Youngstrom, E.A., 2015. Raw data for meta-analysis of discriminative validity of caregiver, youth, and teacher report for pediatric bipolar disorder -- all English publications through End of 2014. Inter-university Consortium for Political and Social Research.

1 TABLES

2 **Table 1. Baseline Characteristics of OXTEXT-1 Cohort**

Characteristic	Percentage	Mean	SD	Range
Age, years		41	13.7	16-76
Female	66.7%			
Ethnicity				
White European	93.5%			
Mixed Black	1.55%			
Mixed Asian	0.31%			
Other	5.64%			
Educational Level				
Undergraduate degree or above	55.2%			
A-levels or equivalent (age 18)	23.6%			
GCSEs or equivalent (age 16)	16.1%			
DSM-IV Diagnosis				
Bipolar 1	62.6%			
Bipolar 2	33.3%			
Bipolar NOS	4.0%			
Age of onset of first depressive episode, years		21.3	9.7	4-57
Mean number of (self-reported) lifetime episodes of depression		22.8	27.5	1-100
Age of onset of first hypomanic/manic symptoms		26.0	11.5	3-72
Number of (self-reported) lifetime episodes of hypomania/mania		Mean: 17.2 Median: 6	22.8 4.4	1-100
Has ever had ≥ 4 mood episodes in one year	64.7%			
Has ever experienced psychotic symptoms	48.5%			
Patient has ever attempted to take their own life	38.9%			
Proportion of lifetime patient reports having spent unwell since onset of mood disorder				
0-49%	36.5%			
50-100%	28%			
Unknown	35.5%			
Length of time using True Colours System (months)		27.6	22.5	1-81 [Median: 21 months]
Medication at entry into study*				
Lithium	32.8%			
Anticonvulsant	42.2%			
Antipsychotic	44.1%			
Antidepressant	37.0%			
Drug free	9.1%			

3 *Medication data shown as percentages of the 265 (89%) of study participants for whom this data
4 was available.

Table 2. Mood Variability

	Variability Score^amean [SD]				
Measure	WHOLE COHORT (n=297)				p-value
QIDS	1.55 [0.54]				N/A
ASRM	1.21 [0.7]				N/A
	FEMALE (n=198)	MALE (n=99)			
QIDS	1.61 [0.56]	1.42 [0.51]			0.003^b
ASRM	1.24 [0.58]	1.16 [0.59]			0.323 ^b
	BIPOLAR 1 (n=187)	BIPOLAR 2 (n=98)	BIPOLAR NOS (n=12)		
QIDS	1.55 [0.49]	1.57 [0.64]	1.38 [0.59]		0.954 ^c
ASRM	1.19 [0.55]	1.27 [0.64]	1.01 [0.5]		0.461 ^c
	Age <20	Age 21-40	Age 41-60	Age >60	
QIDS	1.88 [0.71]	1.68 [0.62]	1.42 [0.4]	1.31 [0.40]	0.0001^c
ASRM	1.67 [0.7]	1.31 [0.66]	1.12 [0.44]	0.94 [0.46]	0.001^c

^bWilcoxon Rank Sum Test ^cKruskall-Wallis Test

^a Variability = $\sqrt{\text{changes per week}}$ where 1 change is equal to a one integer change in score on QIDS/ASRM between weekly questionnaire replies.

Table 3. Comparison of symptomatic course of bipolar disorder in different publications

Reference	Percentage of time spent in mood State (%)				Differences found between diagnostic groups
	Diagnosis	Euthymia	Depression	Hypomania or mania	
This study	Whole cohort	40.1	35.0	7.5	No significant differences between bipolar 1 & 2
	Bipolar 1	41.5	36.5	6.9	
	Bipolar 2	41.2	36.4	7.9	
Faurholt-Jepsen et al, 2015 (Faurholt-Jepsen et al., 2015b)	Bipolar 1	74.0	18.0	5.5	Bipolar 2 spent more time depressed than bipolar 1.
	Bipolar 2	51.0	45.1	2.7	
Bopp et al,2010(Bopp et al., 2010)	Bipolar 1,2, NOS	36.5	47.7	7.0	Bipolar 1 spent more time depressed than bipolar 2
Kupta et al, 2007(Kupka et al., 2007)	Bipolar 1	47.7	36.2	12.5	No significant differences between bipolar 1 & 2
	Bipolar 2	50.2	36.9	10.0	
Joffe et al,2004(Joffe et al., 2004)	Bipolar 1 & 2	53.1	40.9	6.0	No significant differences between bipolar 1 & 2
Post et al, 2003(Post et al., 2003)	Bipolar 1 & 2	52.6	33.2	10.8	No significant differences between bipolar 1 & 2
		Subsyndromal symptoms	Mild mood* symptoms	Syndromal mood* symptoms	<i>*includes depression and mania</i>
Judd et al, 2002(Judd et al., 2002)	Bipolar 1	14.8	20.2	12.3	No significant differences between bipolar 1 & 2
Judd et al, 2003(Judd et al., 2003)	Bipolar 2	15.7	25.2	13.0	


Participants meeting inclusion criteria &
consented for OXTEXT-1 cohort
N= 367

Participants withdrawn
from study
N=39


Participants lost to
follow-up
N=6

**Participants assessed & registered for
True Colours Mood Monitoring System
N=297**

Participants not yet assessed and/or has
yet to start using True Colours (*includes n=2
who are registered but have never returned any
data*)
N=25



Comparison of time spent in different mood states by gender



Competing Interests

GMG reports grants and personal fees from Servier, personal fees from Teva, personal fees from Otsuka, personal fees from Takeda, grants and personal fees from Lundbeck, personal fees from Eisai, personal fees from Lilly, personal fees from Merck, personal fees from GlaxoSmithKline, personal fees from AstraZeneca, and grants from P1vital during the conduct of the study. DJM reports grants from American Foundation for Suicide Prevention and National Institute of Mental Health; and book royalties from Guilford Press and John Wiley and Sons, outside the submitted work. ACB has received salaries from P1vital. All other authors declare no conflicts of interest.

Acknowledgements & Role of the Funding Source

We thank the OXTEXT team for their hard work in recruiting to the cohort; Angus McKnight for writing a macro; Merryn Voysey for statistical advice; and Zoe Reed for assistance in editing the manuscript. JG had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Reference Number RP-PG-0108-10087). JG is a NIHR Senior Investigator. We also acknowledge the provision of facilities for conducting the study by the Oxford cognitive health Clinical Research Facility (NIHR funded), Warneford Hospital, Oxford. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. ACB and LA are supported by a Wellcome Trust Strategic Award (CONBRIO: Collaborative Oxford Network for Bipolar Research to Improve Outcomes, Reference number 102616/Z). The design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript was entirely independent of the funding sources.

Author's Contributions

RM downloaded data, designed and performed analyses and results interpretation and drafted the manuscript. ACB assisted with reference research and helped to draft the manuscript. DJM, GMG, JFG initiated the OXTEXT project, helped design the methodology, helped to interpret findings and provided guidance with the manuscript. CH performed the variability design and analysis. JFG is guarantor.